2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCBone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, bone disorder, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, hereditary disease, laryngeal disorder, musculoskeletal system disorder, neoplasm, osteochondrodysplasia, otorhinolaryngologic disease, respiratory system disorder, squamous cell carcinomaRecruitingPhase 2 / Phase 32026-10-02NCT06788990
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung Cancer (ES-SCLC)RecruitingPhase 32026-08-12NCT06801834